New and Emerging Management Options for Anemia in CKD

CKD Prevalence by Stage

Relationship Between CKD and CVD

Graded and Independent Relationship Between Estimated GFR and CVD Outcomes*

Patients Diagnosed With CKD Have a Greater Likelihood of Death Than Patients With ESRD

Cardiovascular Mortality Is Higher in Patients With ESRD

Anemia as a Complication of CKD

Definition of Anemia in CKD

Role of the Kidney in Erythropoiesis

Factors That Contribute to Anemia in CKD

Prevalence of Anemia* in Patients With CKD by GFR

Anemia Is an All-Cause Mortality Multiplier: Medicare Beneficiaries

Cardiorenal Failure Target Anemia

Impact of Anemia in Patients With CKD Stage 5

Impact of Anemia in Patients With CKD Stage 3-4

Management of Anemia in CKD KDOQI Guidelines

Perspective

Hb Levels Should Be Evaluated in ALL CKD Patients, Regardless of Stage*

Mean Monthly Hemoglobin And Mean EPO Dose per Week Higher Hb With Concomitant Increase in Use of Drugs

Published Randomized Controlled Trials in CKD The Bottom Line

Anemia Correction in CKD Impact on Quality of Life

Great Unknown!

Next Big Question!

Rationale for New Approaches in CKD Anemia

New Drugs HIF-PHI

Role of HIF-PHI in Iron-Restricted, EPO-Deficient Anemias

Prolyl Hydroxylase Inhibitors (HIF Agonists) in Active Clinical Development

Roxadustat Elevates Hb in Stage III-IV CKD Anemia

Roxadustat Elevates Hb With Lesser Decline in Serum Iron as Compared With Epoetin

Roxadustat Achieves Target Hb Within or Near Physiologic EPO Cmax Levels

Hb Response to Oral Roxadustat TIW Without IV Iron in Dialysis-Dependent CKD

Vadadustat Phase 2b -- Hb and Hepcidin Levels

Vadadustat Phase 3 Studies

Daprodustat Phase 2 Change in Hb and EPO levels After Conversion From ESA in DD-CKD

Roxadustat No Impact of Inflammation on Efficacy (NDD and DD-CKD)

HIF-Stabilizers Safety Concerns

HIF-Stabilizers Safety Concerns (cont)

Hepcidin Modulation

Hepcidin Antagonists

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)